| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-193 | |
| Phytochemical name or plant extracts | Bryonia dioica extract | |
| PMID | 31115513 | |
| Literature evidence | These findings suggest that B. dioica could be considered a promising source for developing novel therapeutics against breast cancer. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Aqueous extract | |
| Source of phytochemicals or plant Extracts | Bryonia dioica Jacq | |
| Geographical availability | Albania, Algeria, Austria, Belgium, Bulgaria, Czechoslovakia, France, Germany, Great Britain, Greece, Hungary, Italy, Kazakhstan, Libya, Morocco, Netherlands, Portugal, Sicilia, Spain, Switzerland, Tadzhikistan, Tunisia, Uzbekistan, Yugoslavia | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | The highest inhibitory effect was produced at concentrations of 50 µg/ml or higher after 72 h of treatment (91.15±0.71%). Furthermore, the extract induced apoptosis of MDA‑MB‑231 cells. At 250 µg/ml, 64.61% of the treated MDA‑MB‑231 cells were apoptotic. | |
| Cell line/ mice model | MDA‑MB‑231 | |
| Additional information | The percentage of cells in G2/M increased from 15.7% (untreated cells) to 59.13% (50 µg/ml) and 58.51% (250 µg/ml). The UV‑vis absorption spectra of B. dioica aqueous extract showed two absorption bands characteristic of the flavonol skeleton, 350‑385 nm (Band I) and 250‑280 nm (Band II). | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:291584-1 | |
| Safety | NA |